Viking Therapeutics stock soared as much as 104% on Tuesday after a successful drug trial.
Viking's GLP-1 weight loss drug led to a significant reduction in body weight among patients.
The drug could ultimately compete with weight loss drugs from Eli Lilly and Novo Nordisk if its Phase 3 trials p